STAT+: Novo Nordisk’s next-gen obesity drug stumbles in comparison study
Stat News • 2/23/2026
Summary
No summary yet.
Advertisement
Lindy Score Breakdown (V4.2)
8h
Age
2
Sources
from cluster
7
Hours Since Seen
Final Score25/100
CategoryBreaking
StatusActive
Recency Multiplier90% (0.5^7/48)
Hero EligibleYes
Story Timeline
- 2026-02-23STAT+: Novo Nordisk’s next-gen obesity drug stumbles in comparison study (current)
Score BreakdownRisk 55
Source Reputation: Low-trust source (4/20 pts)
Consensus: Emerging consensus: 2 sources
Age: Breaking news - too recent to assess longevity
Stories gain Lindy status through source reputation, network consensus, and time survival.
Same Story from 2 sources
Breaking Similar stories
STAT+: Novo’s next-gen obesity drug stumbles in Lilly comparison study
Stat News • Today
STAT+: Gossamer lung disease drug fails late-stage study, but company will still seek FDA approval
Stat News • Today
STAT+: Pharmalittle: We’re reading about pharma lobbying, a disappointing Novo clinical trial, and much more
Stat News • Today
STAT+: Nature Medicine to investigate study that found cancer treatment is better in morning
Stat News • 2 days ago
STAT+: A provocative proposal asks the FDA to let some AI devices on the market without review
Stat News • Today
STAT+: People with intellectual and development disabilities have higher rates of anxiety, depression
Stat News • Today
STAT+: Health care reform might be a focus in midterms. For Congress, pursuing it will be an uphill climb
Stat News • Today
STAT+: DOJ, Ohio attorney general accuse OhioHealth of driving up prices, crowding out competition
Stat News • 2 days ago
STAT+: FDA unveils rules for bespoke gene therapies, predicting flood of rare disease applications
Stat News • Today
STAT+: Medicare’s AI ‘modernization’ project, and the Ohio hospital antitrust battle
Stat News • Today